Illuminating histidine phosphorylation in the pancreatic tumor microenvironment

Development of phosphohistidine (pHis) antibodies has significantly advanced our understanding of pHis contributions to tumor biology, including a tumor suppressive role for a pHis phosphatase, a metastasis suppressive role for His kinases, and pHis regulation of T cell receptor signaling. Using these antibodies, we investigated pHis pathway regulation in the mouse pancreatic tumor microenvironment. We identified deregulated expression of pHis and pHis phosphatases that correlated with mouse pancreatic tumor progression. We developed a protocol to circumvent the acid and heat-sensitivity of pHis signals, enabling their co-staining with other proteins in FFPE tissue, identifying a significant enrichment of 1-pHis and a subtype of 3-pHis signals (Gly-3-pHis) in the stroma. We discovered increased Gly-3-pHis levels in tumor-associated myeloid cells mainly resulting from elevated ATP citrate lyase 3-pHis levels and predicted the existence of pHis in cell-cell adhesion proteins. We provide evidence that mitochondrial delocalization of PGAM5, a pHis phosphatase with increased expression during pancreatic tumorigenesis, occurs in tumor cells as compared to stromal cells, enabling access to PGAM5s known cytoplasmic substrate, pHis-NME (Non-MEtastatic), and two potential Gly-3-pHis substrates, SCS (Succinyl CoA Synthetase) and {beta}-catenin. Overall, we introduce a new method and possible targets for future studies of pHis pathway deregulation during tumorigenesis.